Senti Biosciences (SNTI) Research & Development (2021 - 2025)
Senti Biosciences' quarterly Research & Development came in at $7.8 million in Q4 2025, little changed year-on-year from $7.8 million in Q4 2024, and down 26.21% quarter-over-quarter from $10.5 million in Q3 2025.
Senti Biosciences has reported Research & Development for 5 years, with the latest figure at $7.8 million in Q4 2025.
- For the quarter ending Q4 2025, Research & Development changed 0.15% year-over-year to $7.8 million; the trailing twelve-month figure through Dec 2025 stood at $37.6 million (up 9.4% YoY), and the FY2025 full-year result was $37.6 million, up 9.4% from the prior year.
- Research & Development for Q4 2025 stood at $7.8 million, down from $10.5 million in the prior quarter.
- The five-year high for Research & Development was $10.5 million in Q3 2025, with the low at $5.2 million in Q2 2021.
- Average Research & Development over 5 years is $8.0 million, with a median of $7.8 million recorded in 2024.
- Year-over-year, Research & Development surged 76.64% in 2022 and decreased 25.64% in 2023.
- Tracing SNTI's Research & Development over 5 years: stood at $6.4 million in 2021, then advanced by 9.8% to $7.0 million in 2022, then gained by 29.63% to $9.1 million in 2023, then dropped by 14.8% to $7.8 million in 2024, then slipped by 0.15% to $7.8 million in 2025.
- The last three Research & Development figures came in at $7.8 million (Q4 2025), $10.5 million (Q3 2025), and $10.0 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 626,092.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 4.32 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -101.30 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 1.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 961.60 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -2.30 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.54 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 364.87 Mn |
| 10 | Senti Biosciences Holdings | 22.25 Mn | 22.25 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 7.76 Mn |
| Sep 30, 2025 | 10.52 Mn |
| Jun 30, 2025 | 10.03 Mn |
| Mar 31, 2025 | 9.28 Mn |
| Dec 31, 2024 | 7.77 Mn |
| Sep 30, 2024 | 8.66 Mn |
| Jun 30, 2024 | 9.15 Mn |
| Mar 31, 2024 | 8.78 Mn |
| Dec 31, 2023 | 9.12 Mn |
| Sep 30, 2023 | 9.09 Mn |
| Jun 30, 2023 | 6.88 Mn |
| Mar 31, 2023 | 7.06 Mn |
| Dec 31, 2022 | 7.04 Mn |
| Sep 30, 2022 | 6.52 Mn |
| Jun 30, 2022 | 9.25 Mn |
| Mar 31, 2022 | 7.60 Mn |
| Dec 31, 2021 | 6.41 Mn |
| Sep 30, 2021 | 5.41 Mn |
| Jun 30, 2021 | 5.24 Mn |